371 related articles for article (PubMed ID: 21859993)
1. Common gene rearrangements in prostate cancer.
Rubin MA; Maher CA; Chinnaiyan AM
J Clin Oncol; 2011 Sep; 29(27):3659-68. PubMed ID: 21859993
[TBL] [Abstract][Full Text] [Related]
2. ETS rearrangements in prostate cancer.
Rubin MA
Asian J Androl; 2012 May; 14(3):393-9. PubMed ID: 22504874
[TBL] [Abstract][Full Text] [Related]
3. [Dangerous liaisons in prostate cancer. Clinical and biological implications of recurrent gene fusions].
Perner S
Pathologe; 2010 Oct; 31 Suppl 2():121-5. PubMed ID: 20798944
[TBL] [Abstract][Full Text] [Related]
4. ETS fusion genes in prostate cancer.
Gasi Tandefelt D; Boormans J; Hermans K; Trapman J
Endocr Relat Cancer; 2014 Jun; 21(3):R143-52. PubMed ID: 24659477
[TBL] [Abstract][Full Text] [Related]
5. Characterization of TMPRSS2-ETS gene aberrations in androgen-independent metastatic prostate cancer.
Mehra R; Tomlins SA; Yu J; Cao X; Wang L; Menon A; Rubin MA; Pienta KJ; Shah RB; Chinnaiyan AM
Cancer Res; 2008 May; 68(10):3584-90. PubMed ID: 18483239
[TBL] [Abstract][Full Text] [Related]
6. [TMPRSS2-ETS gene fusion in prostate cancer].
Perner S; Schmidt FH; Hofer MD; Kuefer R; Rubin M
Urologe A; 2007 Jul; 46(7):754-60. PubMed ID: 17458530
[TBL] [Abstract][Full Text] [Related]
7. SLC45A3-ELK4 is a novel and frequent erythroblast transformation-specific fusion transcript in prostate cancer.
Rickman DS; Pflueger D; Moss B; VanDoren VE; Chen CX; de la Taille A; Kuefer R; Tewari AK; Setlur SR; Demichelis F; Rubin MA
Cancer Res; 2009 Apr; 69(7):2734-8. PubMed ID: 19293179
[TBL] [Abstract][Full Text] [Related]
8. A fluorescence in situ hybridization screen for E26 transformation-specific aberrations: identification of DDX5-ETV4 fusion protein in prostate cancer.
Han B; Mehra R; Dhanasekaran SM; Yu J; Menon A; Lonigro RJ; Wang X; Gong Y; Wang L; Shankar S; Laxman B; Shah RB; Varambally S; Palanisamy N; Tomlins SA; Kumar-Sinha C; Chinnaiyan AM
Cancer Res; 2008 Sep; 68(18):7629-37. PubMed ID: 18794152
[TBL] [Abstract][Full Text] [Related]
9. ETS gene fusions in prostate cancer: from discovery to daily clinical practice.
Tomlins SA; Bjartell A; Chinnaiyan AM; Jenster G; Nam RK; Rubin MA; Schalken JA
Eur Urol; 2009 Aug; 56(2):275-86. PubMed ID: 19409690
[TBL] [Abstract][Full Text] [Related]
10. Fusion in the ETS gene family and prostate cancer.
Narod SA; Seth A; Nam R
Br J Cancer; 2008 Sep; 99(6):847-51. PubMed ID: 18781147
[TBL] [Abstract][Full Text] [Related]
11. ETS factors in prostate cancer.
Qian C; Li D; Chen Y
Cancer Lett; 2022 Apr; 530():181-189. PubMed ID: 35033589
[TBL] [Abstract][Full Text] [Related]
12. Molecular subtyping of prostate cancer.
Kaffenberger SD; Barbieri CE
Curr Opin Urol; 2016 May; 26(3):213-8. PubMed ID: 26986650
[TBL] [Abstract][Full Text] [Related]
13. Androgen regulation of ETS gene fusion transcripts in prostate cancer.
Gasi D; Trapman J
Methods Mol Biol; 2011; 776():335-48. PubMed ID: 21796535
[TBL] [Abstract][Full Text] [Related]
14. FLI1 is a novel ETS transcription factor involved in gene fusions in prostate cancer.
Paulo P; Barros-Silva JD; Ribeiro FR; Ramalho-Carvalho J; Jerónimo C; Henrique R; Lind GE; Skotheim RI; Lothe RA; Teixeira MR
Genes Chromosomes Cancer; 2012 Mar; 51(3):240-9. PubMed ID: 22081504
[TBL] [Abstract][Full Text] [Related]
15. Recurrent SKIL-activating rearrangements in ETS-negative prostate cancer.
Annala M; Kivinummi K; Tuominen J; Karakurt S; Granberg K; Latonen L; Ylipää A; Sjöblom L; Ruusuvuori P; Saramäki O; Kaukoniemi KM; Yli-Harja O; Vessella RL; Tammela TL; Zhang W; Visakorpi T; Nykter M
Oncotarget; 2015 Mar; 6(8):6235-50. PubMed ID: 25749039
[TBL] [Abstract][Full Text] [Related]
16. ETS gene fusions in prostate cancer.
Clark JP; Cooper CS
Nat Rev Urol; 2009 Aug; 6(8):429-39. PubMed ID: 19657377
[TBL] [Abstract][Full Text] [Related]
17. Molecular profiling of ETS gene rearrangements in patients with prostate cancer registered in REDEEM clinical trial.
Palanisamy N; Tsodikov A; Yan W; Suleman K; Rittmaster R; Lucia SM; Chinnaiyan AM; Fleshner N; Kunju LP
Urol Oncol; 2015 Mar; 33(3):108.e5-13. PubMed ID: 25175425
[TBL] [Abstract][Full Text] [Related]
18. Hormone-sensitive prostate cancer: a case of ETS gene fusion heterogeneity.
Attard G; Jameson C; Moreira J; Flohr P; Parker C; Dearnaley D; Cooper CS; de Bono JS
J Clin Pathol; 2009 Apr; 62(4):373-6. PubMed ID: 19066166
[TBL] [Abstract][Full Text] [Related]
19. Genetic, Environmental, and Nuclear Factors Governing Genomic Rearrangements.
Ramanand SG; Mani RS
Adv Exp Med Biol; 2019; 1210():57-66. PubMed ID: 31900904
[TBL] [Abstract][Full Text] [Related]
20. Emerging Developments in ETS-Positive Prostate Cancer Therapy.
Bowling GC; Rands MG; Dobi A; Eldhose B
Mol Cancer Ther; 2023 Feb; 22(2):168-178. PubMed ID: 36511830
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]